Jordan’s Leading Cancer Center Launches AI Readiness Initiative to Advance Cancer Care
King Hussein Cancer Center has selected ReMedi Health Solutions to lead a…
HMC and Boehringer Ingelheim partner to advance clinical research and healthcare innovation in Qatar
Hamad Medical Corporation and Boehringer Ingelheim have signed an MoU to strengthen…
WHO issues new guidance on Bundibugyo Virus Disease therapeutic research
The World Health Organization (WHO) has called for more research before immunomodulators…
African Countries step up readiness for next-generation TB Vaccines
WHO convened Kenya, Malawi, and Zambia in Nairobi to strengthen preparedness for…
Boehringer Ingelheim launches three phase III trials in precision Oncology
Boehringer Ingelheim has initiated three Phase III clinical trials aimed at advancing…
WHO Releases First-Ever Guidance to Advance Child-Focused Dengue Treatments
WHO has released its first-ever guidance to accelerate the development of child-focused…
Vertex Presents New CASGEVY Data in Children, Expands Global Regulatory Filings
Vertex Pharmaceuticals presented new data showing positive outcomes with CASGEVY in children…
UAE Approves New Oral Breast Cancer Treatment for Hormone-Resistant Cases
The UAE has approved AstraZeneca’s Etcamah, a new oral therapy for advanced…
Sanofi provides update on MOBILIZE phase 3 study of riliprubart in chronic inflammatory demyelinating polyneuropathy
Sanofi has announced the discontinuation of its Phase 3 MOBILIZE study evaluating…
FDA approves Lilly’s EBGLYSS® for one maintenance dose every eight weeks in patients with moderate-to-severe atopic dermatitis
The U.S. FDA has approved a new maintenance dosing regimen for Eli…
